On the same day, the New England Journal of Medicine published two pieces on psychedelic therapy, and neither is about whether it works. One, by Hughes, addresses the collision between state-authorized psychedelic programs and federal Schedule I status. The other, by Zisman-Ilani and colleagues, addresses informed consent and shared decision-making in psychedelic care. The substance of each matters, but the more important fact is the pairing and the venue. The hardest questions in psychedelic therapy are no longer pharmacological. They are jurisdictional and ethical, and they have now reached the most establishment perch in medicine.
Why the venue is the story
For most of the past decade, the public argument about psychedelics was about efficacy: the trial designs, the effect sizes, the unblinding problem, the FDA’s rejection of the first MDMA application. That argument is not finished, a point worth holding onto. But when the New England Journal of Medicine runs two governance-and-ethics pieces on psychedelic therapy at once, it marks a shift in where the action is. The conversation is moving from proving the treatments work to working out how to regulate them, consent to them, and pay for them as they edge toward real-world use. Mainstream-journal attention of this kind does something concrete: it legitimizes the questions and gives them durable citation weight in the policy debates, regulatory proceedings, and legal disputes where the answers will actually be decided.
Dimension one: the jurisdictional collision
The first problem is structural, and it is the cannabis problem transplanted onto psychedelics. State-authorized programs are already operating while psilocybin remains a Schedule I controlled substance under federal law. Oregon’s Measure 109 created the first state-regulated psilocybin services program, with licensed service centers running since 2023 and several hundred licensed facilitators statewide. Colorado, under Proposition 122 and its implementing legislation, conducted its first state-regulated psilocybin session in Denver in June 2025. In both states, adults can legally access psilocybin in a licensed, supervised setting under state law, while the same act remains a federal felony.
The deeper structural issue is the one the desk touched on in covering psilocybin’s path outside North America: the federal government regulates drugs, through the FDA and the DEA, while the states regulate the practice of medicine. Psychedelic-assisted therapy, a scheduled drug bound to a supervised therapeutic encounter, sits precisely on that divide. The state programs are not FDA-approved medicine; they are state-licensed services delivering a federally prohibited substance. A piece in the New England Journal of Medicine naming that conflict precisely gives it establishment-medicine framing that policymakers and courts can cite, which is exactly why it matters more than another advocacy white paper would.
Dimension two: consent
The second problem is ethical, and it is specific to this class of treatment in a way that standard frameworks do not handle well. Informed consent assumes a stable, autonomous decision-maker. Psychedelic therapy alters consciousness and heightens suggestibility, the patient is acutely vulnerable during the session itself, and the facilitator-patient power dynamic is intensified by the experience. Consent obtained beforehand has to govern a state in which the ordinary capacity to withdraw or object is altered.
This is not a theoretical worry. The documented concerns about facilitator conduct in the MDMA trials that fed into the FDA’s rejection of the first application made patient protection a live issue, and practitioners building the state programs have flagged screening, informed consent, and post-session monitoring as exactly the areas where facilitator training is thinnest and the safety data is least mature. A New England Journal of Medicine piece elevating shared decision-making and patient-driven frameworks signals that consent and autonomy are now recognized as a distinct clinical-ethics problem the field has to solve before it scales, not after.
Why the two together matter
Jurisdiction and consent are the two questions that get harder, not easier, as psychedelic therapy moves from trials into programs. Efficacy questions are settled by data and, eventually, by regulators reading the data. Governance and ethics questions are settled by institutions, courts, payers, and licensing boards, which move slowly and contest more. The two papers landing together is a marker that the field has crossed from the prove-it phase into the run-it phase, and the run-it phase is where access, liability, reimbursement, and patient safety are actually determined.
For the audience that tracks this as an industry, that is the practical signal. Mainstream-journal attention to governance and consent is a leading indicator of scrutiny. Payers do not reimburse treatments whose oversight and consent frameworks are contested. Regulators and state boards condition access on them. And the federal-state gap creates real legal and liability exposure for the operators and investors building in the state programs. The NEJM pair foreshadows the non-clinical barriers, jurisdictional risk, consent and liability standards, reimbursement gating, that will decide whether psychedelic therapy reaches scale regardless of how strong the efficacy data becomes.
The timing against the FDA track
This lands as Compass Pathways’ psilocybin program moves toward a regulatory filing. An FDA approval would not simplify the picture; it would sharpen it. An approved psilocybin medicine would coexist uneasily with Schedule I status, forcing the rescheduling question, and it would sit alongside state service-center programs that are not built on the FDA-approval model at all. The jurisdictional and consent questions these papers raise are precisely the ones an approval would force to a head, which is part of why they are surfacing in the NEJM now rather than later.
The disciplined caveats
A few cautions keep the signal in proportion. These are Perspective-style pieces, argument and framing rather than new data, so they signal elite attention, not resolution. The problems they name are well known to people inside the field; what is new is the venue and the simultaneity, which is a statement about mainstreaming rather than a discovery. And the claim that the conversation has moved past efficacy is only half true. Efficacy is not settled, the effect sizes are debated and the unblinding problem the desk has covered repeatedly remains unresolved, so governance attention arriving does not mean the underlying treatments are proven. A governance and consent framework built on top of contested efficacy is its own kind of risk, and the honest reading is that both conversations are now live at once.
The frame
The signal in two New England Journal of Medicine papers on a single day is that psychedelic therapy has entered the phase where its fate turns less on trial results than on how the jurisdictional and ethical questions get answered. For a field that spent a decade arguing about whether psychedelics work, the arrival of governance and consent at the center, and in the NEJM, is both a sign of maturation and a warning. The remaining barriers are increasingly institutional, and institutional barriers are the ones that determine whether a treatment that works ever reaches the people it is meant for.